{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000114","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.257480+00:00","generated_at":"2026-05-17T01:57:48.824640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcus Biosciences reports Q3 2025 net loss $135M; casdatifan shows 12.2 mo mPFS in late-line kidney cancer","bullets":["Net loss of $135M for Q3 2025 vs $92M in Q3 2024; revenue $26M vs $48M.","Casdatifan pooled analysis (n=121) showed 12.2 months median PFS and 35% ORR at 100mg dose in late-line ccRCC.","Taiho exercised option for casdatifan in Japan/Asia for option payment, milestones, and royalties.","Cash and equivalents $841M; funded through PEAK-1 Phase 3 readout.","Domvanalimab + zimberelimab + chemo showed 26.7 months median OS in EDGE-Gastric study."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000114","json":"https://secwatch.observer/filing/0001724521-25-000114.json","markdown":"https://secwatch.observer/filing/0001724521-25-000114.md","text":"https://secwatch.observer/filing/0001724521-25-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000114/0001724521-25-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000114/rcus-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:57:48.824640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}